GeneMedi's Nuclear Receptors portfolio for drug discovery and mechanism of action (MOA) research.

The Nuclear Receptor portfolio of GeneMedi offers a wide range of products that can be used in the analysis of transcription factors that are implicated in numerous diseases such as metabolic diseases, inflammatory diseases, and some forms of cancer. Nuclear receptor proteins are a group of transcription factors that operate through DNA sequence specific binding sites and a mechanism that modulates the expression of target genes. They are very important in the regulation of numerous biological functions including metabolic, developmental, and reproductive functions. Nuclear receptors are choice targets for drug development in the pharmaceutical industry, and can be broadly classified on the basis of their ligand-binding domains and sequence homologs. One prevalent classification divides nuclear receptors into three primary families: For instance, it interacts with steroid hormone receptors, thyroid hormone receptors, and retinoid X receptors. Every family includes a number of important proteins with different functions and uses in treatment.

For instance, steroid hormone receptors include estrogen receptors, androgen receptors, and glucocorticoid receptors in charge of reproduction, immunity and stress respectively. The thyroid hormone receptors are TRα and TRβ; these are important in the regulation of metabolic, growth and developmental processes. Retinoid X receptors exist as three subtypes; RXR α, β, and γ which regulate processes of cell division, cell differentiation, and cell death. The analysis and manipulation of the nuclear receptors and their signaling pathways have led to the development of various diagnostic and therapeutic usages. Nuclear receptors are involved in the development of numerous diseases including cancer, metabolic diseases, and autoimmune diseases and thus are potential targets for drug therapy. Some of the drugs that act on nuclear receptors include agonists or antagonists of hormones and are used in the management of diseases. Furthermore, some nuclear receptors can be employed for the identification of certain diseases. For example, the overexpression or mutation of some of the nuclear receptors has been associated with the development of cancer and its progression and can be used in the diagnosis and assessment of the condition.

Therefore, nuclear receptors are a vast and highly appealing group of targets for drug discovery and development. Due to the intricate signaling pathways and roles they play, they are useful in diagnosis and treatment, and the categorization and identification that has been done presents chances for better treatment and precision medicine. GeneMedi has a large selection of antibodies for Nuclear Receptor research and these are useful for ELISA, affinity binding assays, drug discovery, and mechanism of action (MOA) research. The mAbs in our catalogue are produced using mammalian cell lines and are of high quality and reliability. These mAbs may be used for cell culture, assay development, animal model generation, PK & PD model generation, and MOA studies in the course of a biological drug discovery programme.

Q&A

Q1. What are nuclear receptors?
A1: Nuclear receptors are a sub-group of the superfamily of transcription factors that control transcription of target genes through binding to DNA sequences.

Q2. Which are the major superfamilies of nuclear receptors?
A2Steroid hormone receptors, thyroid hormone receptors and retinoid X receptors are the mainly nuclear receptors.

Q3. How does the nuclear receptor function in disease?
A3: Nuclear receptors are implicated in the development of many diseases; cancer, metabolic diseases, and autoimmune diseases among others.

Q4. What does GeneMedi’s Nuclear Receptor portfolio offer for the research?
A4: GeneMedi’s Nuclear Receptor portfolio is made up of benchmark antibodies for ELISA, affinity binding assays, drug discovery as well as studies on the mechanism of action (MOA).

Q5. In what ways can nuclear receptors be employed in pharmaceuticals?
A5: Nuclear receptors as a target of choice in drug discovery, especially in the pharmaceutical industry. Steroidal and nonsteroidal drugs that act as agonists or antagonists of nuclear receptors are used in the treatment of different diseases.